Trial Profile
Randomized, Double Blind, Placebo Controlled "First-in-human" Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 ( 100 mg, 200 mg, 400 mg and 600 mg ) in Healthy Young Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PBF 677 (Primary)
- Indications Glaucoma
- Focus Adverse reactions; First in man
- Sponsors Palobiofarma
- 15 Sep 2016 Status changed from active, no longer recruiting to completed.
- 08 Jan 2016 New trial record